2017 American Transplant Congress
Pharmakokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV Positive Kidney Transplant Recipients.
BackgroundLimited data exist on the pharmacokinetic (PK) profile of novel direct acting antivirals in kidney transplant recipients (KTR). Here we report the PK of combinated…2017 American Transplant Congress
Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER] Trial.
University of Pennsylvania, Philadelphia
Background: More than 500 kidneys from HCV+ deceased donors are discarded each year, even though direct acting antiviral therapies have cure rates exceeding 95%. We…2017 American Transplant Congress
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.
University of Maryland Medical Center, Baltimore, MD
Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…2017 American Transplant Congress
EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.
Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…2017 American Transplant Congress
Single-Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients.
Nephrology and Kidney Transplant Department, ISCMPA, Porto Alegre, RS, Brazil
Chronic hepatitis C (HCV) infection is a prevalent condition in end-stage renal disease and presents an important clinical challenge in kidney transplant recipients (KTR). Interferon-based…2017 American Transplant Congress
Use of Ledipasvir/Sofosbuvir with or without Ribavirin in Patients Post-Liver Transplant: Evaluation of Real-World Datasets.
PURPOSE: Post-liver transplant(LT) patients with HCV are considered a difficult-to-treat population. Ledipasvir/sofosbuvir(LDV/SOF) +ribavirin(RBV) for 12 weeks is approved in GT1 LT recipients based on the…2017 American Transplant Congress
Kidney Transplantation in HCV+ Recipients in a New Era of Diagnostics and Therapeutics.
Duke University Medical Center, Durham, NC
BackgroundHepatitis-C infected persons (HCV+) evaluated for kidney transplantation receive rigorous staging of their liver disease, often including liver biopsy. Meanwhile, studies have shown that despite…2016 American Transplant Congress
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…2016 American Transplant Congress
Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.
Henry Ford Hospital, Detroit, MI.
Objectives:Evaluate outcomes of Ledipasvir-Sofosbuvir based hepatitis C therapy in liver transplant patients at a single center.Methods:All post-liver transplant patients started on Ledipasvir-Sofosbuvir therapy between January…2016 American Transplant Congress
Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival.
Background: No consensus has been reached regarding comparisons of outcomes for patients with hepatitis C virus (HCV) who received living donor liver transplantation (LDLT) versus…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 28
- Next Page »